Astellas Pharma receives FDA authorization for Xtandi to treat metastatic CRPC The U.S ici . Meals and Drug Administration today approved Xtandi to treat men with late-stage castration-resistant prostate cancer that has pass on or recurred, despite having medical or surgical therapy to minimize testosterone. Approved for prostate cancer sufferers treated with docetaxel, another anti-malignancy treatment, Xtandi was reviewed beneath the FDA’s concern review program. This program offers an expedited six-month evaluate for medications that may offer major advances in treatment or offering a treatment when no adequate therapy is present.
Seventy-five % had been aged 80 years and older and 78 % were female. Overall rates of dementia and additional psychiatric diseases were measured and adequate treatment history reviewed by an expert multidisciplinary panel. Related StoriesMayo Clinic's Florida campus awarded NIH grant to identify vascular risk factors in aging and dementiaLewy Body Composite Risk Rating detects LBD and Parkinson's disease dementia in three minutesCeliac sufferers at no increased risk for dementia, study findsThe researchers found that two-thirds of participants had dementia based on the Diagnostic and Statistical Manual of Mental Disorders.